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Gene expressionIn the last few years, research has focused on single nucleotide polymorphisms (SNPs) in the search for
underlying genetic aetiology of complex disorders. This has been afforded by the rapid technological
advancement to enable the interrogation of hundreds of thousands of SNPs in one assay via microarrays.
However SNPs are only one form of genetic variation and in the midst of the Genome-Wide Association
Study (GWAS) explosion Variable Number Tandem Repeat (VNTR) polymorphism exploration has seemingly
been left behind. This review will argue that VNTR investigations still hold substantial potential for a role in
complex disorders via possible functional properties.
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Many heritable medical disorders, termed ‘complex disorders’ dis-
play no clear Mendelian pattern of inheritance, despite this, evidence
from family studies, and twin concordance rates indicate strong
heritability, and genetic components to their aetiology. Complex dis-
orders are rarely the result of single gene mutations and have three
main features. First, complex disorders are a product of many genes
working with and against each other, for which none are essential
or sufﬁcient for disorder manifestation. In addition these genes will
inﬂuence and be inﬂuenced by additional environmental components.
Secondly, complex disorders are likely to have a high degree of bothrights reserved.environmental and genetic heterogeneity within its aetiology. Finally,
clinical heterogeneity such as symptom proﬁle, severity, and age of
onset creates many sub-types within one disorder [112].
Variable Number Tandem Repeat (VNTR) is an encompassing term
for a DNA sequence motif that is repeated several times in the
genome continuously and that are inherited in a Mendelian fashion.
Despite these VNTRs often being categorised and ignored as ‘junk’
DNA; the number of times the sequence is repeated can differ within
and between individuals therefore making these VNTRs a polymorphic
entity. The term VNTR covers both micro-satellites that are classiﬁed as
motifs of 1–6 bp long and mini-satellites that are made up of longer
continuous motif sequence blocks which can span hundreds of bps.
VNTRs are thought to have arisen due to slippages during DNA replica-
tion or as a consequence of unequal crossing-over, and due to the repet-
itive nature of the sequence have allowed further increases/decreases in
274 K.J. Brookes / Genomics 101 (2013) 273–281the number of repeats resulting in the polymorphisms observed [106].
They are estimated to represent 3% of the genome and are frequently
found in promoters and potential functional locations within genes,
suggesting that theymay have an impact on several phenotypes [35,68].
2. Current state of play
The decades of research to identify underlying gene variations
responsible for complex disorders have; despite some moderate
successes; largely failed in the task to reliably distinguish causal vari-
ants. Initial linkage studies of multi-affected families were generally
underpowered to identify the genes, which underlie the aetiology of
such disorders, suggesting that the original estimates of effect sizes for
the genetic variations were inﬂated, and the number of genes involved
was conservative [103]. A move towards the ‘common disorder, com-
mon polymorphism’ ideology followed, which believed that the under-
lying genetic aetiology would come from polymorphisms that were
found frequently in the population, and not rare mutations that have
often been identiﬁed in single-gene disorders [67].
With the advances made in genotyping technologies, laboratories
moved to candidate gene association studies. Identifying genes with
biological evidence to play a role in the aetiology and testing the poly-
morphisms that lay within for associationwith their disorder of choice.
Over the years, projects grew from investigating single polymorphisms
to several polymorphisms and genes at once. Due to the limited ability
to only investigate single nucleotide polymorphisms that created/
abolished restriction enzyme cut sites, VNTR polymorphisms became
a popular choice for investigation. Sadly it became ever more obvious
that the effect sizes of the genes involved were smaller than the ﬁeld
ever imagined, and to attain enough power to detect them bigger sam-
ple sizes were called for. Due to the cost of collecting larger samples, the
cost in genotyping needed to decrease. SNP genotyping led the ﬁeld
with the advent of microarray technology allowing thousands of SNPs
to be genotyped on a single array. As technology progressed, the
genotyping of SNP markers became easier and cheaper, and soon hun-
dreds of thousands of SNP markers could be genotyped at once, and
the dawn of Genome-Wide Association Study (GWAS) began.
Despite the success in the development of high-throughput SNP
genotyping, high-throughputVNTRgenotyping has not beendeveloped.
The very nature of the VNTRs led to technical problemswith genotyping
on the array platforms that SNP genotyping utilises, complicating the
scoring of the number of repeats present. Furthermore, VNTR polymor-
phisms were often named after their location in the gene and had no
structured nomenclature or human speciﬁc databases such as SNPs
with their rs# logged into national database such dbSNP for easy access
to information [109]. Finally the complex mutation pattern observed in
VNTR polymorphisms led to different alleles being associated with the
same disorder between populations; for example the DRD4 gene exon
3 VNTR association with ADHD is with different alleles for European
(7-repeat) and Asian (2-repeat) populations due to when the alleles
evolved and the selective pressures on them, therefore adding complex-
ity in interpreting results of the causal risk variant [17,127].
3. The potential of VNTR polymorphisms
Although GWAS has fulﬁlled its task and identiﬁed a number of
replicable novel SNP association ﬁndings [52,123]; it only explains a
small amount of the heritability behind complex disorders [76–78]. In
addition, the association ﬁndings tend to be isolated SNPs that are
intergenic, and to assign functional content to them will not be easy. It
is feasible that single base changes in the DNA sequence have functional
consequences for example they may alter the binding afﬁnity of pro-
teins that either enhance or repress gene expression, however their
effect is also likely to dependon the presence or absence of other factors.
In addition SNPs identiﬁed in GWAS do not amount to the estimates
calculated by quantitative genetic studies; and so we are left with“missing heritability”, which has been hypothesised to lie with other
polymorphism such as VNTRs [46], however, an in-depth discussion of
this phenomenon is outside the scope of this review and is adequately
discussed elsewhere in the literature [76–78,98].
For these reasons I would like to argue in favour of the investigation
of VNTR polymorphisms and their potential functional consequences. If
one takes a look into the literature, there are thousands of publications
on VNTRpolymorphisms; detailing their associationswith disorders (or
failures to ﬁnd association), their interactions with the environment
and other genes with multiple review articles for any given disorder,
and therefore the association ﬁndings will not be discussed here. How-
ever there are also many publications about how VNTR polymorphisms
affect the functionality of the gene.
Due to the nature of VNTR polymorphisms, they can be proposed to
beﬁne tuners of gene expression. As common polymorphisms are likely
to have small effect sizes edging the risk by a single ‘notch’ towards/
away for a given phenotype; the multiple alleles of a given VNTR
allow more scope for functional consequences than perhaps biallelic
SNPs and therefore may be easier to observe. In addition the greater
potential which VNTR polymorphisms have for mutation means that
theymay have a role to play in the evolution of speciﬁc higher organism
traits, such as behaviour [35].
Using examples from the literature, I wish to highlight the functional
consequences of the VNTR alleles and propose that VNTR polymor-
phisms should not be forgotten and hope that this review will re-
ignite the study of VNTR polymorphisms within complex disorders.
4. Coding polymorphisms
The most likely candidates for functional VNTR polymorphisms
are those that lie within the coding regions of the gene, therefore
directly affecting the protein product. An example of this is the VNTR
that lies within the third exon of the dopamine receptor D4 (DRD4)
gene. Originally identiﬁed in the early 1990s [70], it has received
ample attention due to its speculated involvement in AttentionDeﬁcient
Hyperactivity Disorder [65], and its high afﬁnity for clozapine, a treat-
ment for schizophrenia [120].
This 48 bp repeat unit has been observed to extend between 2 and
11 imperfect tandem repeats, with the most common alleles being
the 2-, 4- and 7-repeat, although there is population variation in
frequency [29]. The tandem repeat affects the putative third cytoplasmic
loop of the receptor protein, altering its length by 16 amino acids with
each tandem repeat. When activated by an agonist, via G-protein
coupling, such as dopamine, the receptor is thought to inhibit cAMPpro-
duction by decreasing the activity of adenylyl cyclase [24,120] and
therefore it might be feasible to believe that the VNTR polymorphism
would affect the receptor function. Initial reports investigating the
VNTR effect on pharmacological action in cell lines suggested that the
binding afﬁnity of clozapine, an antagonist of the receptor, was similar
for the three common alleles of the VNTR (2-, 4- and 7-repeats).
However, in the presence of sodium chloride, the binding afﬁnity of
clozapine increased for constructs containing the2- and 4-repeat alleles,
with the 7-repeat allele showing a similar binding afﬁnity as in the
absence of sodium chloride. This would suggest that the effect of the
VNTR is only observed in certain conditions, and that the 7-repeat allele
might have reduced sensitivity to the salt concentration in the cell.
Despite the observation of these small pharmacological differences
between alleles, further studies found little impact on pharmacological
action in constructs with the smallest and longest tandem repeats
[57], and those with the VNTR deleted [4].
A later study investigated the level of cAMP formation in order to
observe if the alleles had functional relevance rather than of pharma-
cological action [3]. Observation of forskolin stimulated dopamine
inhibition of cAMP levels in cell lines containing constructs of the three
common alleles suggested that there was a blunted response in cells
carrying the 7-repeat allele, with the 2- and 4-repeat alleles displaying
275K.J. Brookes / Genomics 101 (2013) 273–281greater inhibition of adenylyl cyclase than the 7-repeat allele [3]. The
2-repeat allele has also been shown to exhibit a blunted response in
comparison to the 4-repeat allele, but midway between that and the
7-repeat allele [29,127]. In addition, a study by Kazmi et al. [60] investi-
gated the effects of the VNTR variants on the G-protein coupling prop-
erties of the DRD4 receptor. Using two different methods, the group
conﬁrmed that the third cytoplasm loop was required for G-protein
coupling; however there was no quantitative difference in the coupling
between constructs of the 2-, 4- and 7-repeat alleles.
Recently, it has been identiﬁed that dopamine itself acts as a chaper-
one protein to stimulate dopamine receptor D4 protein synthesis, in a
dose-dependent manner [119]. The exon 3 polymorphism is thought
to affect the extent to which dopamine can increase protein folding
and therefore synthesis. Van Craenenbroeck et al. [119] investigated
the three common alleles of the polymorphism and their chaperone
induced up-regulation by dopamine. Dopamine was found to up-
regulate the alleles to different extents, with the 2-repeat showing
the least up-regulation from baseline (without dopamine), and the
7-repeat displaying the highest level of up-regulation, with the 4-repeat
displaying an intermediate response. Interestingly the 7-repeat had the
lowest levels of protein synthesis at baseline, although not signiﬁcantly
different from the other alleles.
In silico analysis of the VNTR sequence has identiﬁed the presence
of potential Src Homology 3 (SH3) binding motifs in the repeated 16
amino acid sequence of the third cytoplasmic loop, which provides
modular binding domains for protein–protein interactions. Synthesised
labelled fragments, of the most common allele (4-repeat allele), were
found to bind strongly to other proteins that had SH3 binding domains;
NCK1 and Growth factor Receptor Bound protein 2 (GRB2) [90]. When
full-length cDNA constructs of the three common alleles were com-
pared, the 7-repeat allele was found to display the strongest interaction
with NCK1 and GRB2 proteins versus the 2- and 4-repeat alleles [90].
Constructswith a deletion of the SH3 domains, failed to be able to inhibit
cAMP formation via forskolin stimulated dopamine binding, although
binding afﬁnity did not differ, suggesting that the protein interactions
facilitated through the SH3 domains, might regulate the action of the
receptor [90].
Finally, other studies have investigated whether the VNTR affects
DRD4 gene expression, both in vitro [107] and in vivo [111]. Electro-
phoretic mobility shift assays of a 72 bp construct containing a single
repeat unit and 12 bp ﬂanking sequence either side, with nuclear
extract from HeLa cells suggest that the VNTR repeat unit is capable
of binding a protein. Increases in the concentration of the nuclear
extract revealed several bands, suggesting that multiple different
proteins can bind to the genomic sequence of the repeat unit [107].
Follow-up luciferase assays comparing constructs of the three most
common alleles displayed little expression variation between them
when placedwithin the promoter, but displayed a signiﬁcant difference
when residing in the 3′UTR. The observations suggested that there was
decreased expression of the reporter when the construct contained the
7-repeat allele in comparison to the shorter alleles [107]. This observa-
tion has been supported by in vivo investigations of DRD4 gene expres-
sion in human post-mortem pre-frontal cortex samples. Simpson et al.
[111] compared expression of the DRD4 gene between human samples
with different exon 3VNTR alleles. Despite no signiﬁcant results, aweak
trend was observed for lower gene expression in individuals with one
or more 7-repeat alleles at the VNTR polymorphism.
5. Promoter polymorphisms
Gene promoters are prime targets in the search for regulatory
polymorphisms due to their potential to affect the binding of the
transcriptional machinery. Therefore it is unsurprising that many
functional VNTR polymorphisms have been identiﬁed in this area. A
prime example is that of tri-nucleotide expansion polymorphisms
found in Fragile-X Syndrome and Huntington's disease [116].Within the literature there are several examples of promoter VNTR
polymorphisms associated with complex disorders with the potential
to be functional [126,128,136]. In particular there are a number of
studies that concentrate on the promoter VNTR polymorphisms within
the Insulin (INS) gene, Serotonin Transporter (5HTT/SLC6A4) gene and
the Monoamine Oxidase A (MAOA) gene. The functionality of the sero-
tonin transporter gene polymorphism has recently been comprehen-
sively covered elsewhere and therefore shall not be included here [44].
One of the most successful VNTR polymorphism associations has
been between the VNTR within the promoter region of the insulin gene
and Type 1Diabetes (T1D). The insulin gene lies on the long arm of chro-
mosome11with aVNTRpolymorphism residing 365 bpupstream to the
transcription start site, consisting of an imperfect 14–15 bp tandem
repeat sequence [10,11]. The VNTR has been classed into three alleles
dependant on its length: Class I consists of 28–44 repeat units; Class II
45–137 repeat units and Class III 138–159 repeat units. Class II alleles
are very rare in populations other than in African samples, and in
Caucasian samples the Class I allele has a frequency of approximately
70%. It is the Class I alleles that have been found to be associated
with T1D, repeatedly across investigations and populations
[6,10,41,101,125].
The same VNTR has also been associated with polycystic ovary
syndrome [34], type 2 diabetes [80], and other related traits such as
obesity, BMI [50,51] and weight at birth [91,93], however these asso-
ciations have had less replicated success [15,47,74,133].
Despite some question over the association of the alleles with
disorders and traits; functional analyses suggest potential for the
VNTR to alter expression of the mRNA in a tissue speciﬁc fashion. In
vitro reporter gene constructs of the VNTR alleles, in both fetal rat islets
and hamster insulin producing β-cell lines, display similar evidence
suggesting the Class III alleles result in higher expression of the insulin
gene, in comparison to the shorter Class I alleles [61]. In addition, this
group also found evidence suggesting that the Pur-1 transcription factor
binds the repeat unit, and is the mechanism behind the transcription
level. Compared to a reporter construct without the VNTR, transcription
was increased 25% with the presence of Class I alleles, and 200% with
Class III alleles when in the presence of Pur-1 [61]. This work was repli-
cated in human fetal thymus cells, which also indicated that Class III
alleles had higher expression than Class I [118]. However conﬂicting
data from studies in both human adult and fetal pancreas cells suggest
that Class III alleles have a marginally lower gene expression than
Class I alleles [12,13,73,117], and may reﬂect the availability of Pur-1
in different cells.
In a more recent study, it has been proposed that the autoimmune
regulator (AIRE) genewhichunderliesAutoimmunePolyendrocrinopathy
Type 1 Syndrome (APS1) might regulate the insulin gene via the VNTR
[19]. The insulin promoter Class I alleles have been found to be associated
with APS1 in individuals with T1D [94]. Using hamster pancreatic β-cell
lines, Class I allele constructs were found to have higher expression than
Class III, although both classes were found to be similar when AIRE was
overexpressed in these cells. In contrast, when using human thymic epi-
thelial cell lines derived from six individual DNA samples, they observed
that the Class III alleles displayed higher transcriptional activity than the
Class I alleles in the presence of AIRE. In addition, DNA–protein binding
experiments found that AIRE bound to both Class I and Class III constructs
[19]. With this evidence and that from previous data, Cai and colleagues
hypothesised that within the thymus, a critical region for identifying self
proteins, low expression of the insulin gene might lead to T1D, which is
due to an autoimmune destruction of the pancreatic β-cells.
A different promoter VNTR considered to be functional is that
located approximately 1.2 kb upstream to the ﬁrst exon of the Mono-
amine Oxidase A (MAOA) gene, positioned on the X-chromosome. The
30 bp repeat unit has been identiﬁed with tandem repeats in the
order of 2, 3, 3.5, 4 and 5, with the 4-repeat allele being the common
allele and the 2-repeat being very rare [104]. The VNTR has been asso-
ciated with a varying number of behavioural disorders and traits,
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[54,72,105] and in females the longer alleles with panic disorder [27].
Initial in vitro studies agree that in comparison to the 3.5 and
4-repeat alleles the 3-repeat allele displayed diminished transcriptional
activity. Three groups comparing constructs of the alleles in neuroblas-
toma cell lines found that the 3-repeat allele was associated with
decreased expression [27,104], although their ﬁndings disagreed with
the extent of transcriptional ability of the 5-repeat, with Sabol et al.
[104] reporting that the 5-repeat showed reduced expression similar
to the 3-repeat, and [27], suggesting that the 5-repeat allele displayed
expression activity similar to the 3.5 and 4-repeat alleles. The third
conducted by Guo et al. [42], only compared the expression of 2-, 3-
and 4-repeat allele constructs, ﬁnding that expression level correlated
positively with the number of repeats [42].
A further study using protein extractions of ﬁbroblast cells
cultured from male human samples measured MAOA protein concen-
tration and there too found that extracts from those with 3-repeat
alleles were lower in activity than those with the 4-repeat allele [28].
In opposition, a comparison ofMAOA gene expressionwithin the pineal
gland from post-mortem brains of Alzheimer's patients and controls
suggested that although Alzheimer's patients with the 3.5- and 4-
repeat alleles display higher levels of gene expression than the 3-
repeat, this trend was not observed in the control population [130].
This highlights the fact that polymorphisms may act differently in dis-
eased and healthy tissues.
Recently, new methods for determining transcriptional activity
have been developed for identifying allele speciﬁc expression in
ex vivo samples, such as post-mortem brain tissue. The utilisation of
quantitative PCR methods detects an imbalance of expression of one
allele over the other in mRNA, using genomic DNA as a reference. In
the case of testing a promoter VNTR such as this, a coding marker
SNP that is in high linkage disequilibrium with it, is required as the
VNTR polymorphism is not transcribed. This method was employed
in two studies [25,97], and both found that the MAOA transcript was
subjected to allelic expression imbalance (AEI), proposing that one
allele was transcribed in preference over the other, and this AEI was
indicative of a continuous trait [25]. However both studies failed to
be able to correlate the AEI with the number of promoter tandem
repeats. As the MAOA gene is located on the X-chromosome
X-inactivation may have played a role in these observations (despite
the knowledge that the MAOA escapes X-inactivation), however, AEI
was not found to coincide with which chromosome was inactivated.
In addition, some methylation was observed at the promoter of the
gene in female subjects but not in males, suggesting another form of
gene compensatory mechanism.
Despite the failure of correlating AEI with genotype at the VNTR,
in silico analyses have identiﬁed potential sites that the VNTR could
control transcription of the MAOA gene. The repeat unit itself lies
within a CpG island, and holds three speculative methylation sites,
and therefore the degree for putative methylation of the promoter
could be inﬂuenced by the number of repeats present [110]. Moreover,
the VNTR has been found to contain Sp1 transcription factor binding
sites, therefore suggesting further functional relevance [113]. However,
in both cases these in silico investigations need to be experimentally
veriﬁed.
6. Other polymorphisms
Although the functional relevance of VNTR polymorphisms located
within introns and outside the gene coding sequence, such as the 3′
UTR is less certain, they still hold potential to play a role in alternative
splicing, mRNA translocation, stability and translation efﬁciency [82].
An example of this is found in the dopamine transporter (DAT1/
SLC6A3) gene, located on chromosome 5. Like many of the other
VNTRs mentioned here, this one has also been associated with behav-
ioural traits and namely a robust candidate for Attention HyperactivityDeﬁcit Disorder [26]. The 48 bp repeat unit is found in tandem repeats
of 7 through to 11, with 9 and 10-repeat units being themost common.
Aswithmost VNTRs sequence variation has been observed amongst the
repeats [84].
Unfortunately the functional studies of this polymorphism have
shown less concord than the others discussed here. Over the years
there have been numerous studies that have tested the functional
effects of the VNTR polymorphism in the 3′UTR of the DAT1 gene
using reporter gene assays and transient transfection in mammalian
cell cultures [39,40,81,84,85,121].
The VNTR was initially deemed a functional candidate when the
insertion of the VNTR construct containing the 9-repeat allele upstream
to a SV40 promoter with GFP reporter gene, transfected into midbrain
derived cells from neonatal rats displayed enhanced expression of the
gene in comparison to the construct without the VNTR [81].
Comparison of all observed alleles of the VNTR polymorphism
suggested that the 10-repeat allele induced the highest expression
of the reporter gene [39]. Contrastingly, Miller & Madras [85] found
that the 9-repeat allele enhanced gene expression to a higher degree
than the 10-repeat allele. More recently VanNess et al. [121], created
four DAT1 constructs; two constructs contained the 3′UTR VNTR one
with the 9-repeat allele, one with the 10-repeat allele, the third with
just the coding region and a fourth with a truncated 3′UTR prior to
the VNTR location. DAT binding assays that were performed in human
embryonic kidney HEK-293 cells indicated that the 10-repeat allele of
the VNTR had 50% higher DAT binding than the 9-repeat allele. Howev-
er constructs lacking the VNTR displayed the highest DAT binding of all,
indicating that the VNTRmay control the level of DAT protein produced.
Yet other in vitro studies have revealed no signiﬁcant differences in
transcription between the 9 and 10-repeat alleles when cloned down-
stream of the luciferase gene and in the presence of either the SV40 or
the DAT1 homologous promoters in SK-N-SH, SN4741, HEK293 or
SH-SY5Y cells [40,84], therefore indicating the VNTRmay affect transla-
tion efﬁciency rather than transcription.
Yeast-one hybrid screens using the 10-repeat VNTR allele as bait
identiﬁed a potential modulator of expression [38]. This led to a series
of experiments that investigated the level of reporter gene expression
in relation to the VNTR alleles and the presence of the transcription
factor. Hairy/Enhancer of Split Related transcription factor 1 (HESR1/
HEY1) was found to differentially negatively regulate the expression
of a reporter gene construct dependant on the presence of different
VNTR alleles. In comparison to the 10-repeat allele, the 7-repeat allele
was found to result in signiﬁcantly higher expression, whilst the
11-repeat allele was found to show signiﬁcantly diminished expression.
The 9-repeat allele displayed an intermediate level of expression be-
tween the 7- and 10-repeat alleles but did not reach signiﬁcance [38].
Later research found that HESR2 andHESR3 also displayed a similar pat-
tern of inhibition on gene expression via the 3′UTR polymorphism [58],
potentially suggesting a negative relationship between VNTR length
and gene expression.
Studies using post-mortem samples from different areas of the
brain seem to converge suggesting that the 10-repeat allele conveys
higher mRNA expression in comparison with individuals with the
9-repeat allele [16,83], however a recent study using a larger sample
detected no association of VNTR genotype with mRNA expression
levels [96]. Furthermore, allelic expression imbalance investigation
of post-mortem brain tissue from Alzheimer's patients, displayed
signiﬁcant differences in expression between the coding marker SNP
alleles, however these could not be associated with the VNTR polymor-
phism [96].
7. Points for consideration
As can be observed from the above examples, delineating the true
functional effects of VNTR polymorphisms on gene function is by no
means easy or complete. In general the picture painted by both
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gree of complexity. Even if functional consequences can be
established, and concur with directionality, the outcome of such func-
tions might not correlate with a single disorder. Therefore many
points must be considered when investigating the potential of
VNTRs to play a role in the development of traits and disorders via
functional means.
Firstly, the determination of functional properties for a VNTR will
be contributed by the complement of factors, e.g. other proteins that
act on the DNA sequence of the VNTR, present in the cell. Therefore
the VNTR may seem to have functional effects in one cell type, none
in another and opposite consequences in yet another. Likewise in one
disorder compared to another. Therefore the observation of functional-
ity within investigations can also depend on the methodology used, in
vivo versus in vitro and which tissue or cell lines are utilised. Although
in silico analyses and hypotheses are useful, they always need to be
conﬁrmed by experimental means, which as seen numerous times in
the literature, generate conﬂicting results. These discrepancies may be
due to the employment of different strategies, which offer different
advantages and disadvantages.
Whilst in vitro investigations bring an element of control for
experimental conditions, can be carried out without the need of
human samples, and be easily replicated between studies; differences
between cell lines, constructs and vectors between investigations can
be a source for the conﬂicting data observed in the literature. The
utilisation of different cell lines, location of the VNTR polymorphism
construct within the reporter gene, and the type of reporter gene
could all lead to differing effects. Additionally, different reporter con-
structs can exploit different promoters (viral versus endogenous pro-
moters) and therefore could lead to variation between studies. Finally
the different cell types may contain factors that interact with the
VNTR polymorphisms that would not be found in the native in vivo
cell, and vice versa [134].
For example in the exploration of the DAT1 3′UTR VNTR polymor-
phism the use of monkey epithelium cells in the Fuke et al. [39] study
is a questionable substitute for representatives of the human brain
cells. Whilst both the Michelhaugh et al. [40,81] studies utilised the
substania nigra derived SN4741 cell lines, cells from the midbrain
known to contain dopaminergic cells, the line was derived from
mouse embryonic cells, which again may be questionable substitutes
for human brain cells although it may be more representative of what
is likely to be occurring in in vivo brain cells in comparison to other
cells used in these studies. Furthermore, despite the utilisation of the
same cell lines, the two studies observed conﬂicting results. Whilst
Michelhaugh et al. [81] suggested that the presence of the VNTR
enhanced transcription of the gene (at least with the 9-repeat allele);
experiments by Greenwood and Kelsoe [40] failed to observe any
increase in gene transcription. An important point to note here is that
in the Michelhaugh et al. [81] study the VNTR construct was inserted
upstream to the reporter gene and not in its native 3′ location. This
may have altered its functional properties. The HEK-293 cells utilised
in three studies [84,85,121] are derived from human embryonic kidney
cells, although found to be naturally dopamine transporter producing
cells, the function and usage of these transporters may not be exact
to that of transporters found in the brain. In addition, the various
conﬂicting observations between the studies could be due to the vary-
ing sequence lengths of the VNTR and surrounding DNA inserted into
the reporter gene constructs.
Generally investigations using in vivo disease tissues would be
expected to possess the same within-cell factors that impact on the
VNTRDNA sequences however, investigations involving human samples,
both those measuring mRNA expression and AEI although carried out in
the subject and tissue of interest also have caveats that need to be
addressed. Post-mortem sample sizes generally tend to be small in com-
parison to association studies, and could consist of varying unknown life-
style factors, for example alcohol consumption and smoking are knownto affect the level of DAT1 gene expression [30,63,79]. Furthermore,
pre-mortem (agonal) and post-mortem factors need to be considered
carefullywhen collecting human autopsy samples. Firstly, agonal factors,
which include speciﬁc conditions at the time of death and agonal dura-
tion, are known to decrease brain tissue pH and signiﬁcantly affect RNA
integrity and abundance and thus have a major impact on gene expres-
sion [8,99]. Secondly, post-mortem factors such as condition of the tissue
after death, post-mortem interval (PMI) and duration of brain tissue
storage in the freezer also affect RNA integrity [7,114]. These studies
show that post-mortem intervals of 48 h do not affect expression levels.
Furthermore post-mortem samples are not always from individuals that
were affected with the disorder being investigated and therefore the
mRNA levels observed may be due to the effects of the disorder rather
than the polymorphism. However, controlling for these factors is not
realistic. In addition different cell types exist in one tissue, and not all
may express the gene of interest, and therefore the level of expression
may depend on the number and type of cells present in the tissue.
Furthermore in investigations of AEI it is questionable whether the
bi-allelic SNPs used as markers truly can represent the multiple alleles
of the VNTR polymorphisms.
Further complexity is added when considering that the DNA se-
quence of these tandem repeats is often imperfect copies of each other,
which could potentially be different between constructs if not controlled
for, adding yetmore variation. Although this strengthens thehypotheses
that VNTR polymorphisms may be functional as it gives a greater scope
to create variable expression levels, it also makes it more difﬁcult to
determine the direction of the functionality and so great care must be
taken when publishing to include such data as DNA sequence used in
constructs, or detailed sequencing of human samples used.
For example in the case of the serotonin transport promoter VNTR
where it has been reported that the short allele has lower transcriptional
activity than the long allele [49,87]. However the long allele also
contains an A/G SNP (rs25531) that is not present in the short allele;
long alleles carrying the G-allele have been found to show activity
similar to the short allele and therefore if not taken into consideration
will impede investigations of functionality [53,88].
In summary the question becomes what is the best way to investi-
gate functionality? Is it better to have every investigation using exactly
the same method, or will this lead to bias in the results, due to experi-
mental artefacts? Can we trust the observations made to be real or
just due to experimental methods? So although differing procedures
might not produce the same results all the time, if the effect of the
VNTR polymorphism is robust enough to overcome experimental
differences, so that all the data points in the same direction, it could
then be construed as functional. Of course this should not mean that
the experimental design can be anything, it should strive to try and
mimic the endogenous in vivo conditions as much as possible, which
means using endogenous promoters, inserting the VNTR to be explored
in its natural context with as much of the native gene sequence as pos-
sible, as it is likely that the polymorphism in question works in tandem
with other variants along the gene sequence. Trying to match cell lines
to those where the VNTR polymorphism is speculated to have an effect
is also important, so that endogenous transcription factors and other
proteins that might contribute to the functionality are as similar to the
in vivo cells as possible. It is anticipated that these types of methodolo-
gies will be used as technological advances are accomplished.
Once functionality of a VNTR polymorphism has been established
to a level of certainty, the next step would be to try and determine the
immediate outcome of this function. This may depend on whether the
polymorphisms affect the levels of transcription, translation or some
other measure of gene expression. For instance what does a decrease
in the expression of the insulin gene in the thymus lead to, what are the
knock-on effects, and the biochemical outcomes? Is less protein made?
Is there a quantitative change in the number of T-cells produced?
Likewise, how do the allelic variations in the pancreatic insulin gene
expression change reactions to blood glucose levels? Can we correlate
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such changes to occur in logical directionality e.g. higher insulin produc-
tion leads to a greater decrease in blood glucose levels, the question is to
what extent does this occur in relation to the polymorphism under in-
vestigation, and what other factors contribute to this.
This nicely leads on to the question about how does the presence of
other gene variants and environmental factors affect the consequences
of the polymorphism under investigation. The original estimates of
heritability of complex disorders involved only additive genetic and
environmental effects, however it is unlikely to be this simple and inter-
actions are speculated to play a role, therefore new strategies are being
developed in order to address this [135]. For example, the effect of a
drug used to treat a disorder may depend not only on the genotype at
the point of action for the drug, but also on genes that may affect the
metabolism of the drug (e.g. [18]). Theoretically polymorphisms within
the same gene may also show both additive and interactive effects
resulting in different outcomes. Hypothetically, if the presence of
the 7-repeat allele at the DRD4 gene leads to a blunted response, but
another polymorphism in the promoter of the gene, such as the
120 bp duplication [108], leads to an increase in gene transcription,
the elevated levels of receptor might overcome the effects of the
blunted response and result in a normal downstream biochemical
outcome.
With the accumulation of GWAS, there is ample data to analyse
epistasis between genes and between polymorphisms, and in recent
years many algorithms have been developed for this [20,132]. The
results of thisworkmaybe the creation of SNP panels that are associated
with disorders and traits in an empirical way, free of previous
hypotheses [37,69].
The many thousands of samples present in GWAS suggest that
they may be large enough to detect the effect size of the interactions
[62] but even so may not appreciate the level of heterogeneity present
in complex disorders. Therefore signals may be lost, in the background
noise of so many samples with heterogeneous phenotypes; however,
creating panels based on related functional polymorphisms such as
VNTRs and investigating the biochemical/gene expression results,
might overcome this, and produce clearer data.
As suggested by Caspi et al. [22,23] ignorance of environmental
variables may cause some genetic inﬂuences of small effect to be
overlooked in samples, therefore leading to the inconsistencies ob-
served across samples for genetic association. For example, association
studies for the MAOA promoter VNTR have used the classiﬁcation of
the low and high expressing alleles for a priori hypothesis for
gene × environment investigations. There have been many studies
investigating a modifying effect of the MAOA gene; with some ﬁnding
that the lowexpressing genotype (3-repeat allele) leads to the presence
of antisocial behaviour when childhood maltreatment has occurred
[22,32,33,36]. However, even this has not been fully replicated with
other studies failing to ﬁnd the correlation [43,55]. Furthermore, the
situation is complicated with investigations ﬁnding a modifying effect
but with the opposing allele in female samples, hinting that gender
may also play a role in this associations [5,100,124], adding yet another
factor consideration.
The same can be said of when testing functionality of polymor-
phisms, the effect of a variant allele might only be observedwhen a cer-
tain environment/condition is present, for instance it could be possible
that the extent of the VNTR effect on insulin gene expressionmight only
be observed when there is a high amount of glucose in the blood.
Although complex, and difﬁcult to interpret, investigation of interac-
tions must continue in order to advance further in the ﬁeld of complex
disorders despite facing a number of hurdles. The ﬁrst hurdle is that of
methodology. Investigations into possible interactions have become
the norm, with new ideas of how best to approach investigations
forming constantly. The fact that even between a few factors, multiple
interactions could occur, therefore, which ones are investigated, and if
all are analysed, what of the multiple testing issues? The approachthat has been suggested by Mofﬁtt [86] might provide a good structure
for such investigations. Mofﬁtt [86] proposes that deliberate testing of
gene–environmental interactions needs to take place with a prior
hypotheses behind the interaction being tested, to limit multiple test-
ing. They suggest that several steps be taken. The ﬁrst must be consulta-
tion of quantitative genetic studies and the identiﬁcation of a candidate
environmental risk factor. Secondly optimisation of the environmental
factor measurement must be addressed followed by identiﬁcation of
candidate genes relating with both the disorder and environmental
factor, with plausible biological mechanisms. Testing for interaction
can then commence with evaluation of whether the interaction can be
extended beyond the gene–environment-disorder triad. Finally replica-
tion and meta-analyses are required to support the ﬁnding.
Another suggestion for testing such interactions and correlations
[71] is to look for genetic contributions to speciﬁc environmental/
biochemical triggered events, causing speciﬁc biological phenotypes
rather than a disorder as a whole. The ascertainment of biochemical
alterations in relation to genotype and environmental events would
improve the biological plausibility of the ﬁnding, with measurement
of a biochemical marker more reliable than diagnosis in some complex
disorders.
In addition, and as a consequence of these interactions the
epigenome may also be altered, and ultimately change the functional
outcome of a polymorphic allele. Epigenetics is likely to be the mecha-
nism bywhich the environment and other gene interactions exert their
effects and therefore markers of epigenetic changes should also be
taken into consideration when investigating functional effects of
polymorphisms. Potentially, for example, methylation quantiﬁcation
in and around the polymorphism could be used as a proxy for any un-
known variables affecting the functionality of the target polymorphism.
In the fall out of the GWAS era, it has become apparent that disor-
ders share common underlying features, which are genetically con-
trolled, leading to the same genes and polymorphisms being
associated with different phenotypes [21,102]. In addition it is plausi-
ble that the effects of functional polymorphisms associated are both
temporal and spatial, taking cues from other factors to determine
one outcome over the other.
If we look closer at the different phenotypes the polymorphisms
are associated with, it might convey information about the internal
mechanisms they have in common andwhy in such cases as the insulin
gene VNTR, one allele is associatedwith one disorder and the otherwith
different features. T1D has been robustly associated with the presence
of Class I (or absence of protective Class III) alleles at the promoter
VNTR polymorphism of the insulin gene locus [6,10,41,101,125].
Although not afﬁrmed it seems that tissue speciﬁcity may be important
in the functional role of these alleles. In the thymus, which is part of the
immune system, the Class I alleles seem to predispose for lower expres-
sion of the insulin gene. In the thymus, proteins expressed by the body
are produced, and if the immune systems' T-cells respond to these pro-
teins the T-cells are destroyed before circulating the body, to prevent
autoimmunity. Hypothetically, if low levels of insulin are produced in
the thymus, the T-cells might not detect the protein, and therefore
will not mount a response, resulting in these T-cells progressing into
the body, and leading to T1D. In reality this is likely to require further
genetic components and environmental insults to either lower insulin
production in the thymus to low enough levels to cause this kind of
response.
In contrast, the Class III allele of the same polymorphism has been
associated with disorders such as T2D, obesity and polycystic ovary
syndrome, and with traits such as increased birth weight, head
circumference and BMI [31,56,92,129]. These disorders and traits
have been found to associate with each other [66,75,95]. T2D diabetes
is a result of decreased insulin production from pancreatic β-cells
accompanied with insulin resistance. Observations that the presence
of Class III alleles at the insulin locus results in decreased expression
of insulin in the pancreas [12,13,73,117], and added environmental
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that there is no agreement in the directionality of the associated al-
leles with connected biochemical events, such as response to glucose
suggests that other factors, both genetic and/or environmental also
play a role [2,9,15,51]. Although this is purely speculative and very
much simpliﬁed it demonstrates how one polymorphism might have
differing effects dependent on different factors and how if followed up
one can move through biochemical changes and up to traits and
disorders.
8. The future
VNTRs offer the potential to be functional units of variance, and
therefore should not be forgotten when searching for genetic aetiology
behind complex disorders. Although the identiﬁcation and analyses of
such polymorphisms present challenges, as technological methods
improve like it has done for SNP detection, the exploration of their
effects in the underlying biology of how systems function will become
easier.
Currently the development of next-generation sequencing tech-
niques has enabled the cheap sequencing of the entire genome. In
order to be able to do this the sequence reads have become smaller cov-
ering only 50–150 bp, in comparison to the 800–900 bps produced by
the older capillary based systems. Repeated regions in the DNA cause
problems for the alignment of sequences, and genome assembly due
to the assembly methods being unable to discern where the repeat
lies resulting in difﬁculties for identiﬁcation of tandem repeats versus
interspersed repeats, their true copy numbers and whether the repeat
is polymorphic. Next-generation sequencing with its small read sizes
has made this more difﬁcult, as ideally to be able to accurately align
the sequence with the genomic reference the read has to be longer
than the repeated region, incorporating unique sequences either side
of the repeated unit [115].
The detection of copy number variants by sequencingmethods gives
hope that perhaps with the development of more sensitive algorithms
(and along with increased read lengths), VNTRs will also be able to be
aligned accurately [48,64,131]. Moreover, a recent study has shown
that simple tandem repeats used for identiﬁcation in forensic science
have been genotyped with high accuracy on a short-read next genera-
tion sequencing platform [14]. It can then be hoped that the detection
of de novo tandem repeats is not too far in the future.
Until a time where the high through-put of VNTR polymorphism
genotyping is feasible it may be possible to infer VNTR alleles through
LD with its surrounding SNP variants [45]. Given the number of SNP
markers that can be genotyped for an individual it could be possible to
use linkage disequilibrium and haplotype blocks to deduce the VNTR
variant at any given locus. Recently this has been shown to be possible
with the accurate calling of the serotonin promoter VNTR alleles by
SNP haplotypes [122]. Single SNP markers may not be able to account
for themulti-allelic variation of VNTRpolymorphismshowevermultiple
SNP haplotypes may be able to accurately call the likelihood of which
allele is present. Vinkhuyzen et al. [122] were able to call the serotonin
transporter promoter genotype using a two-SNP haplotype from
commercially available platforms. The TA haplotype of SNP markers
rs2129785 and rs11867581 was found to be in high LD (r2 > 0.75)
with the short allele of the VNTR, and therefore could be used as proxies
to identify the presence of this variant. Using methodology such as this
would allow the mass ‘genotyping’ of VNTRs for analysis. This could be
aided by the genotyping of the samples within the International
HapMap project for the most prevalent VNTRs within the literature.
Improved detection on a genome-wide scale is only half of the
problem that needs to be addressed; better methods of determining
functionality also need to be developed and current ones extended
to different applications. For example, Chromatin Immuno-
Precipitation (ChIP) assays could be a useful technique to test in silico
predictions of transcription factor bindings that are altered by VNTRpolymorphisms. Chromatin extracted from individuals with different
genotypes may exhibit varying amounts of sequence bound to the
transcription factor, and therefore combined with either sequencing
or qPCR, could identify both SNP and VNTR polymorphisms that affect
binding.
In addition, stem cell derivatives could offer an invaluable alternative
to cell lines, and post-mortem ex vivomethodologies. Studies show that
stem cells obtained from dental pulp have the potential to differentiate
into several different cell types, including neural cells [1,59,89], and
therefore could be used for more accurate in vivo conditions in reporter
gene assays.
In summary, perhaps a novel framework of research into complex
genetics will start with the identiﬁcation of potential functional
candidates, like VNTR polymorphisms. In alliance with GWAS and next-
generation sequencing studies, providing gene networks to explore for
functional VNTR polymorphisms, a bottom-up approach could be
employed. With the utilisation of an array of techniques, functional
properties, if present, with directionality could be accredited to the
polymorphism being investigated. The knowledge would then be used
to take educated guesses as to what biological systems will be affected
and link observations of biochemical changes with other polymor-
phisms and environmental factors. The differences in underlying bio-
logical function, and/or structure, can then be related back to complex
disorders, helping develop understanding, treatment and diagnosis
along the way.
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